Rode L., Nordestgaard B. G., Bojesen S. E. Long telomeres and cancer risk among 95 568 individuals from the general population // International Journal of Epidemiology. 2016 Oct; 45 (5): 1634–1643.
Whittemore K., Vera E., Martínez-Nevado E., Sanpera C., Blasco M. A. Telomere shortening rate predicts species life span // PNAS. 2019 Jul; 116 (30): 15122–15127.
Tian X. et al. Evolution of telomere maintenance and tumour suppressor mechanisms across mammals // Philosophical Transactions of the Royal Society B. 2018 Mar; 373 (1741): 20160443.
Gorbunova V. & Seluanov A. Coevolution of telomerase activity and body mass in mammals: From mice to beavers // Mechanisms of Ageing and Development. 2009 Jan – Feb; 130 (1–2): 3–9.
Frenck R. W., Blackburn E. H., Shannon K. M. The rate of telomere sequence loss in human leukocytes varies with age // PNAS. 1998 May; 95 (10): 5607–5610.
Bodnar A. G. et al. Extension of life-span by introduction of telomerase into normal human cells // Science. 1998 Jan; 279 (5349): 349–352.
Jaskelioff M. et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice // Nature. 2010 Nov; 469: 102–106.
De Jesus B. B. et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer // EMBO Molecular Medicine. 2012 Aug; 4 (8): 691–704.
Muñoz-Lorente M. A., Cano-Martin A. C., Blasco M. A. Mice with hyper-long telomeres show less metabolic aging and longer lifespans // Nature Communications. 2019 Oct; 10: 4723.
Baird D. M., Rowson J., Wynford-Thomas D., Kipling D. Extensive allelic variation and ultrashort telomeres in senescent human cells // Nature Genetics. 2003 Jan; 33: 203–207.
De Jesus B. B., Schneeberger K., Vera E., Tejera A., Harley C. B., Blasco M. A. The telomerase activator TA-65 elongates short telomeres and increases health span of adult/old mice without increasing cancer incidence // Aging Cell. 2011 Aug; 10 (4): 604–621.
Fernandez M. L. et al. TA-65, a telomerase activator improves cardiovascular markers in patients with metabolic syndrome // Current Pharmaceutical Design. 2018 May; 24 (17): 1905–1911 (7).
См. п. 59.
Salvador L., Singaravelu G., Harley C. B., Flom P., Suram A., Raffaele J. M. A natural product telomerase activator lengthens telomeres in humans: a randomized, double blind, and placebo controlled study // Rejuvenation Research. 2016 Dec; 19 (6): 478–484.
Abdul-Aziz A. M. et al. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment // Blood. 2019 Jan; 133 (5): 446–456.
Pedesen J. et al. Declining cancer incidence at the oldest ages: Hallmark of aging or lower diagnostic activity? // Journal of Geriatric Oncology. 2019 Sep; 10 (5): 792–798.
Bonafé et al. What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians // Experimental Gerontology. 2002 Oct – Nov; 37 (10–11): 1263–1271.
Franceschi C. et al. Accelerated bio‐cognitive aging in Down syndrome: State of the art and possible deceleration strategies // Aging Cell. 2019 Feb; 18 (3): e12903.
De la Rosa J. et al. Prelamin A causes progeria through cell-extrinsic mechanisms and prevents cancer invasion // Nature Communications. 2013 Aug; 4: 2268.
Fernandez P., Scaffidi P., Markert E., Lee J.-H., Rane S., Misteli T. Transformation resistance in a premature aging disorder identifies a tumor-protective function of BRD4 // Cell Reports. 2014 Oct; 9 (1): 248–260.
Higa K. C. & DeGregory J. Decoy fitness peaks, tumor suppression, and aging // Aging Cell. 2019 Mar; 18 (3): e12938.
Van Heemst D. et al. Variation in the human TP53 gene affects old age survival and cancer mortality // Experimental Gerontology. 2005 Jan – Feb; 40 (1–2): 11–15.
Zhao Y. et al. A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models // eLife. 2018 Mar; 7: e34701.
См. п. 110.
Baker D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders // Nature. 2011 Nov; 479 (7372): 232–236.
Baker D. J. et al. Naturally occurring p16Ink4a-positive cells shorten healthy lifespan // Nature. 2016 Aug; 530 (7589): 184–189.
Palmer A. K. et a. Targeting senescent cells alleviates obesity‐induced metabolic dysfunction // Aging Cell. 2019 Mar; 18 (3): e12950.
Patil P. et al. Systemic clearance of p16INK4a ‐positive senescent cells mitigates age‐associated intervertebral disc degeneration // Aging Cell. 2019 Mar; 18 (3): e12927.
Zhu Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs // Aging Cell. 2015 Mar; 14 (4): 644–658.
Yousefzadeh M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan // EBioMedicine. 2018 Oct; 36: 18–28.
Spindler S. R., Mote P. L., Flegal L. M., Teter B. Influence on longevity of blueberry, cinnamon, green and black tea, pomegranate, sesame, curcumin, morin, pycnogenol, quercetin, and taxifolin fed iso-calorically to long-lived, f1 hybrid mice // Rejuvenation Research. 2013 Apr; 16 (2): 143–151.
См. п. 122.
Justice J. N. et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study // EBioMedicine. 2019 Feb; 40: 554–563.
Van Deursen J. M. Senolytic therapies for healthy longevity // Science. 2019 May; 364 (6441): 636–637.
http://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-reports-promising-topline-data-phase-1-first.
Baar M. P. et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging // Cell. 2017 Mar; 169 (1): 132–147.e16.
См. п. 59.
Ozvari B., Nuttall J. R., Sotgia F., Lisanti M. P. Azithromycin and Roxithromycin define a new family of "senolytic" drugs that target senescent human fibroblasts // Aging. 2018 Nov; 10 (11): 3294–3307.
Li W., He Y., Zhang R., Zheng G., Zhou D. The curcumin analog EF24 is a novel senolytic agent // Aging. 2019 Jan; 11 (2): 771–782.
См. п. 123.
Ritschka B. et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration // Genes & Development. 2017; 31: 172–183.
Blagosklonny M. V. Paradoxes of senolytics // Aging. 2018 Dec; 10 (12): 4289–4293.
Читать дальше
Конец ознакомительного отрывка
Купить книгу